A Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan/Amlodipine/Rosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 265 participants.

Also called NCT03009487

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 265 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03009487
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03009487. Randomized; double masking; primary purpose treatment. Start 2017-01 (actual); primary completion 2018-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan/Amlodipine/Rosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia
Condition
Hypertension
Condition
Hyperlipidemias
Intervention (Drug)
Amlodipine/Olmesartan 10/40mg (Combination drug), Rosuvastatin 20mg
Intervention (Drug)
Olmesartan 40 mg, Rosuvastatin 20mg
Intervention (Drug)
Amlodipine/Olmesartan 10/40mg (Combination drug)
Lead sponsor
Daewoong Pharmaceutical Co. LTD. (class: industry)

Record details

Record id
cardio:ct-nct03009487
Content hash
87972eebbd1ae5805d161b4d05e572a4fa6897ecfab771d4c738330a0ce4bd84